Mazur A
J Clin Invest. 1968 Oct;47(10):2230-8. doi: 10.1172/JCI105908.
Assay of the enzyme ferrochelatase in marrow, liver, spleen, and red cells has been employed to assess the extent of erythropoietic stimulation in animals bearing the Walker 256 carcinosarcoma and in rats treated by administration of phenylhydrazine, cobalt chloride, human urinary erythropoietin, or chronic blood loss. In all instances, the spleen sustains the most marked increase of ferrochelatase activity, per gram of tissue. Spleen erythropoietic activity stimulation was confirmed by quantitative measurements in respiring slices of (59)Fe and (14)C incorporation into hemoglobin and ferritin. Increased spleen ferrochelatase activity in cobalt chloride-treated rats is prevented by actinomycin D, indicating that stimulated synthesis of the enzyme is associated with the metabolism of RNA.
通过检测骨髓、肝脏、脾脏和红细胞中的铁螯合酶，来评估携带Walker 256癌肉瘤的动物以及经苯肼、氯化钴、人尿促红细胞生成素处理或慢性失血的大鼠的红细胞生成刺激程度。在所有情况下，每克组织中脾脏的铁螯合酶活性增加最为显著。通过对（59）Fe和（14）C掺入血红蛋白和铁蛋白的呼吸切片进行定量测量，证实了脾脏红细胞生成活性受到刺激。放线菌素D可阻止氯化钴处理的大鼠脾脏铁螯合酶活性增加，这表明该酶的合成受刺激与RNA代谢有关。
